OverviewSuggest Edit

Anika Therapeutics develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair.  It offers a spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care and skin rejuvenation. The company's proprietary technology is based on hyaluronic acid, a naturally occurring polymer found throughout the body vital for proper joint health and tissue function. Its products include MONOVISC, ORTHOVISC, and ORTHOVISC mini used in the treatment of osteoarthritis; HYVISC used in the treatment of equine osteoarthritis; ELEVESS cosmetic dermal filler with lidocaine; ANIKAVISC viscoelastic for ophthalmic surgery; INCERT-S anti-adhesion surgical gel; and next generation products for joint health, advanced wound care, and other applications.
TypePublic
Founded1992
HQBedford, MA, US
Websiteanikatherapeutics.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)154(+16%)
Job Openings25
Revenue (FY, 2020)$130.5 M(+14%)
Share Price (Oct 2021)$41.7
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Anika Therapeutics

Cheryl Blanchard

Cheryl Blanchard

Director, President and Chief Executive Officer
James Loerop

James Loerop

Executive Vice President of Business Development and Strategic Planning
David Colleran

David Colleran

Executive Vice President, General Counsel and Corporate Secretary
Michael Levitz

Michael Levitz

Executive Vice President, Chief Financial Officer and Treasurer
Thomas Finnerty

Thomas Finnerty

Chief Human Resources Officer
James Chase

James Chase

Vice President of International Sales and Marketing
Show more

Anika Therapeutics Office Locations

Anika Therapeutics has offices in Bedford, Franklin and Padova
Bedford, MA, US (HQ)
32 Wiggins Ave
Franklin, MA, US
28 Forge Pkwy
Padova, IT
Corso Stati Uniti, 4
Padova, IT
Via della Ricerca Scientifica
Show all (4)

Anika Therapeutics Financials and Metrics

Anika Therapeutics Revenue

Embed Graph
View revenue for all periods
Anika Therapeutics's revenue was reported to be $130.46 m in FY, 2020
USD

Revenue (FY, 2020)

130.5m

Gross profit (FY, 2020)

69.0m

Gross profit margin (FY, 2020), %

52.9%

Net income (FY, 2020)

(24.0m)

EBIT (FY, 2020)

(28.3m)

Market capitalization (15-Oct-2021)

599.5m

Closing stock price (15-Oct-2021)

41.7

Cash (31-Dec-2020)

95.8m

EV

524.6m
Anika Therapeutics's current market capitalization is $599.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

64.8m71.4m75.1m105.6m93.0m103.4m113.4m105.6m114.6m130.5m

Revenue growth, %

41%(12%)11%

Cost of goods sold

26.8m29.0m22.8m20.9m21.1m24.0m27.4m31.3m28.7m61.4m

Gross profit

38.0m42.4m52.3m84.7m71.9m79.4m86.1m74.3m85.9m69.0m
USDQ2, 2011

Financial Leverage

1.4 x
Show all financial metrics

Anika Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

151

Patents (US)

21

Patents Licensed

95

Patents Pending

14
Show all operating metrics

Anika Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Anika Therapeutics Online and Social Media Presence

Embed Graph

Anika Therapeutics News and Updates

Dermal Facial Fillers Market | Evolving Opportunities with AbbVie Inc. and Anika Therapeutics Inc. | Technavio

NEW YORK, Aug. 19, 2021 /PRNewswire/ -- The dermal facial fillers market size is expected to reach a value of USD 1.45 billion at a CAGR of 9.14%, during 2021-2025. This marks a significant market slowdown compared to the 2020 growth estimates due to the impact of the COVID-19 pandemic in...

Outlook on the Soft Tissue Allografts Global Market to 2026 - Featuring Allosource, Anika Therapeutics and Cook Medical Among Others

Dublin, July 15, 2021 (GLOBE NEWSWIRE) -- The "Global Soft Tissue Allografts Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Insights on the Osteoarthritis Treatment Global Market to 2029 - Featuring Sanofi, GlaxoSmithKline and Anika Therapeutics Among Others

DUBLIN, July 8, 2021 /PRNewswire/ -- The "Osteoarthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering. The global...

South and Central America Extracellular Matrix Market Demand, Segmentation, Recent Trends, Strategies To 2027 | Top Players Like Organogenesis Inc., Integra Life Sciences Corporation, Mölnlycke Health Care AB, Anika Therapeutics, Inc., ACell Inc.

The South and Central America extracellular matrix market was valued at US$ 989.99 thousand in 2019 and is projected to reach US$ 11,708.44 thousand by 2027; it is expected to grow at a CAGR of 7.1% from 2020 to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

New Study: Sports Medicines Market to register steady expansion during 2018 – 2025| Key Players Included: Anika Therapeutics, Arthrex, Breg, BSN Medical

HTF MI recently introduced Global Sports Medicines Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2025. Posted via Industry Today. Follow us on Twitter @IndustryToday

Facial Aesthetics 2018 Global Market Key Players – Allergan, Anika Therapeutics, Contura, Ipsen, Merz Pharma – Analysis and Forecast to 2022

WiseGuyRerports.com Presents “Global Soft Ice Cream Machines Market Report 2018” New Document to its Studies Database. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Anika Therapeutics Blogs

Anika Reports Second Quarter 2021 Financial Results

Revenue growth of 24% year-over-year Company raises full year revenue growth outlook to 11-14% BEDFORD, Mass. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its

Anika to Host its 2021 Virtual Investor Day on June 3, 2021

BEDFORD, Mass. , May 13, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to host its 2021 Virtual Investor Day on Thursday, June 3, 2021 beginning at 9:00am EDT .

Anika Reports First Quarter 2021 Financial Results

Anika Reports First Quarter 2021 Financial Results Content Import Thu, 05/06/2021 - 16:13 Anika Reports First Quarter 2021 Financial Results May 6, 2021 at 4:05 PM EDT This release is a backfill from a News Wire Earnings Revenue lower…

Anika to Participate in the Sidoti Spring Virtual Investor Conference

BEDFORD, Mass. , March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard , President and Chief Executive Officer and Michael Levitz , Executive Vice President, Chief

Anika Reports Fourth Quarter and Year-End 2020 Financial Results

Anika Reports Fourth Quarter and Year-End 2020 Financial Results Content Import Thu, 03/04/2021 - 16:06 Anika Reports Fourth Quarter and Year-End 2020 Financial Results March 4, 2021 at 4:05 PM EST This release is a backfill from a News Wire Ear…

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021 Content Import Tue, 02/09/2021 - 15:00 Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021 February 9, 2021 at 3:00 PM EST Thi…
Show more

Anika Therapeutics Frequently Asked Questions

  • When was Anika Therapeutics founded?

    Anika Therapeutics was founded in 1992.

  • Who are Anika Therapeutics key executives?

    Anika Therapeutics's key executives are Cheryl Blanchard, James Loerop and David Colleran.

  • How many employees does Anika Therapeutics have?

    Anika Therapeutics has 154 employees.

  • What is Anika Therapeutics revenue?

    Latest Anika Therapeutics annual revenue is $130.5 m.

  • What is Anika Therapeutics revenue per employee?

    Latest Anika Therapeutics revenue per employee is $847.1 k.

  • Who are Anika Therapeutics competitors?

    Competitors of Anika Therapeutics include Ajinomoto Althea, Lipidor and Spear Pharmaceuticals.

  • Where is Anika Therapeutics headquarters?

    Anika Therapeutics headquarters is located at 32 Wiggins Ave, Bedford.

  • Where are Anika Therapeutics offices?

    Anika Therapeutics has offices in Bedford, Franklin and Padova.

  • How many offices does Anika Therapeutics have?

    Anika Therapeutics has 4 offices.